Last reviewed · How we verify
carbamazepine oxcarbazepine
Oxcarbazepine blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizure propagation.
Oxcarbazepine blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizure propagation. Used for Partial-onset seizures (monotherapy and adjunctive therapy), Generalized tonic-clonic seizures (adjunctive therapy), Bipolar disorder (off-label use).
At a glance
| Generic name | carbamazepine oxcarbazepine |
|---|---|
| Sponsor | Odense University Hospital |
| Drug class | Anticonvulsant / Antiepileptic agent |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Oxcarbazepine is a keto-analogue of carbamazepine that stabilizes inactivated sodium channels, limiting repetitive neuronal firing. It also modulates high-voltage-activated calcium channels. These actions reduce the spread of seizure activity across neural networks, making it effective for seizure control.
Approved indications
- Partial-onset seizures (monotherapy and adjunctive therapy)
- Generalized tonic-clonic seizures (adjunctive therapy)
- Bipolar disorder (off-label use)
Common side effects
- Dizziness
- Somnolence
- Headache
- Ataxia
- Diplopia
- Nausea
- Hyponatremia
- Rash (including Stevens-Johnson syndrome, rare)
Key clinical trials
- Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study (PHASE3)
- Comparison b/w Carbamazepine vs Oxcarbazepine in Treatment of Trigeminal Neuralgia (NA)
- Population Pharmacokinetics of Antiepileptic in Pediatrics
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
- Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers (PHASE1)
- Comparison of Oxcarbazepine Versus Carbamazepine in the Management of Trigeminal Neuralgia (PHASE4)
- Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carbamazepine oxcarbazepine CI brief — competitive landscape report
- carbamazepine oxcarbazepine updates RSS · CI watch RSS
- Odense University Hospital portfolio CI